Literature DB >> 7847448

Molecular biology, virulence, and pathogenicity of mycobacteria.

T M Shinnick1, C H King, F D Quinn.   

Abstract

The diseases resulting from infections with Mycobacterium species are important sources of morbidity and mortality throughout the world today, with particularly devastating effects in tropical and developing countries. Almost 2 billion people have been infected with Mycobacterium tuberculosis, the causative agent of tuberculosis, and approximately 3 million people die each year from this disease. Tuberculosis also has re-emerged as an important public health problem in the United States, and this resurgence has been accompanied by an increased incidence of tuberculosis resistant to the standardly used anti-tuberculosis drugs. Researchers' ability to investigate the molecular basis of the pathogenicity and drug resistance of the mycobacteria has been hampered by a lack of appropriate experimental tools. However, during the past 5 years, tremendous progress has been made in the development of the molecular biology of mycobacteria, and molecular tools are now available for detailed analysis of their genetics and for elucidation of the molecular mechanisms of their pathogenicity. The development of these tools is briefly reviewed, and the uses of the tools to investigate drug resistance in Mycobacterium tuberculosis, to identify mycobacterial virulence factors, and to explore intracellular survival strategies are described.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7847448     DOI: 10.1097/00000441-199502000-00007

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  9 in total

1.  Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages.

Authors:  J Wei; J L Dahl; J W Moulder; E A Roberts; P O'Gaora; D B Young; R L Friedman
Journal:  J Bacteriol       Date:  2000-01       Impact factor: 3.490

2.  Increased intracellular survival of Mycobacterium smegmatis containing the Mycobacterium leprae thioredoxin-thioredoxin reductase gene.

Authors:  B Wieles; T H Ottenhoff; T M Steenwijk; K L Franken; R R de Vries; J A Langermans
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Structure of Mycobacterium tuberculosis thioredoxin in complex with quinol inhibitor PMX464.

Authors:  Gareth Hall; Tracey D Bradshaw; Charles A Laughton; Malcolm F Stevens; Jonas Emsley
Journal:  Protein Sci       Date:  2011-01       Impact factor: 6.725

4.  Evaluation of Mycobacterium tuberculosis genes involved in resistance to killing by human macrophages.

Authors:  B H Miller; T M Shinnick
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

5.  Solution structures of Mycobacterium tuberculosis thioredoxin C and models of intact thioredoxin system suggest new approaches to inhibitor and drug design.

Authors:  Andrew L Olson; Terrence S Neumann; Sheng Cai; Daniel S Sem
Journal:  Proteins       Date:  2013-01-15

6.  Mycobacterium tuberculosis PE_PGRS17 promotes the death of host cell and cytokines secretion via Erk kinase accompanying with enhanced survival of recombinant Mycobacterium smegmatis.

Authors:  Tian Chen; Quanju Zhao; Wu Li; Jianping Xie
Journal:  J Interferon Cytokine Res       Date:  2013-05-10       Impact factor: 2.607

7.  Functional studies of multiple thioredoxins from Mycobacterium tuberculosis.

Authors:  Mohd Akif; Garima Khare; Anil K Tyagi; Shekhar C Mande; Abhijit A Sardesai
Journal:  J Bacteriol       Date:  2008-08-22       Impact factor: 3.490

8.  An in vitro tissue culture bilayer model to examine early events in Mycobacterium tuberculosis infection.

Authors:  K A Birkness; M Deslauriers; J H Bartlett; E H White; C H King; F D Quinn
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Experience with ARDS caused by tuberculosis in a respiratory intensive care unit.

Authors:  Ritesh Agarwal; Dheeraj Gupta; Ashutosh N Aggarwal; Digamber Behera; Surinder K Jindal
Journal:  Intensive Care Med       Date:  2005-07-09       Impact factor: 17.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.